Nerviano Medical Sciences
Hugues Dolgos serves as the Chief Executive Officer of NMS Group since January 2022, overseeing an integrated R&D organization focused on advancing patient health through innovative drug development, particularly in oncology. In addition to this role, Hugues holds multiple positions within NMS Group's subsidiaries, including Chairperson of the Board for Accelera and NerPharMa, and Chairperson of the Board and CEO for Nerviano Medical Sciences, each dedicated to different aspects of pharmaceutical development and manufacturing. Hugues previously held significant roles at Servier, Merck Group, and Merck Serono, contributing to the advancement of oncology, biopharmacy, and strategic R&D initiatives. Hugues is also involved with advisory positions at CERES BRAIN Therapeutics and Skymab Biotherapeutics, focusing on innovative therapeutic solutions. Hugues’ academic background includes education from Université Paris Cité.
This person is not in any offices
Nerviano Medical Sciences
Nerviano Medical Sciences is part of NMS Group and it is focused on the discovery and early development of oncology drugs. Our business model is to partner our drugs at late preclinical or early clinical stage for full development and commercialization. Our mission is to pursue innovative therapeutic approaches in Oncology, discovering and developing molecules with novel mechanisms of action, for the advancement of personalized care of cancer patients. An experienced and lean management team leads a highly skilled staff of professionals with international experience and a broad range of expertise in R&D, combining the flexibility of a biotech with the quality standards of a big pharma.